NCT06795282View on ClinicalTrials.gov

Post Operative Sensitivity of MTA Obturation

Not yet recruitingOBSERVATIONAL

Enrollment

105

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

January 1, 2026

Study Completion Date

December 1, 2026

Conditions

Dental Pulp DiseaseEndodontically Treated TeethEndodontic Disease

Interventions

DRUG

MTA

MTA is primarily composed of tricalcium silicate, dicalcium silicate, bismuth oxide (for radiopacity), and small amounts of calcium sulfate. MTA is highly biocompatible, making it suitable for use in the root canal system and areas in close contact with tissues.

All Listed Sponsors

lead

TC Erciyes University

OTHER

NCT06795282 - Post Operative Sensitivity of MTA Obturation | Biotech Hunter | Biotech Hunter